M3 Group extends reach in Iberian and Latin American markets with partnership

Share this article:
Aki Tomaru
Aki Tomaru

MDLinx owner M3 Group is partnering with Argentine online CME firm Medcenter on a content-sharing deal that will expand its in-language reach to Spain, Portugal and Latin America.

Medcenter will join M3's Networks in Health, an “international alliance of online physician communities that provides pharmaceutical, medical device and other healthcare companies services for reaching and engaging doctors across Europe, the Americas and Asia.”

“We're trying to be global,” said Aki Tomaru, CEO of M3 USA. Tomaru said that while M3's Doctors.net.uk runs pan-European campaigns, pharmas are increasingly shopping for broader buys that hopscotch across global markets.

“They want to cherry-pick the countries,” said Tomaru. Until now, he added, that meant either partnering with a different in-culture shop in each country or distributing their content in English through WebMD's Medscape (with which Medcenter had a previous affiliation). “The willingness of most physicians in non-English-speaking countries to spend time on English language materials is limited,” said Tomaru.

Medcenter boasts a network of 480,000 physicians. M3, a Sony-owned Japanese conglomerate whose portfolio includes M3.com in Japan, US-based MDLinx and UK-based Doctors.net.uk, claims more than a million physician members worldwide.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...